#7

Klauber & Jackson
Attorneys At Law
Continental Plaza
411 Hackensack Avenue
Hackensack, New Jersey 07601

TELEPHONE: (201) 487-5800

THE FIRM'S FACSIMILE TRANSMITTERS:
(201) 343-1684 or (201) 343-7544

TO:	Examiner Marianne DiBrino
FROM:	Martha Bussanich
DATE:	October 3, 2002
PAGES TO FOLLOW:	3

Message:

Dear Examiner DiBrino:

As per our telephone conversation, following is the proof of mailing and the Marked-upVersion for the Preliminary Amendment. Thank you.

Martha Bussanich

File No. 1300-1-008 Fax Tel No. 703-746-5244

If you have any questions regarding compatibility, you may reach us at (201) 487-5800.



EXPRESS MAIL
UNITED STATES POSTAL SERVICE®

POST OFFICE TO ADDRESSEE

EL 758521582 US

ORIGIN (POSTAL USE ONLY)

PO ZIP Code: 07661 | Day of Delivery: ☐ Next ☐ Second | Flat Rate Envelope: ☐

Date In: Mo. 5 Day 10 Yr 01 | ☐ 12 Noon ☐ 3 PM | Postage: $ 16.00

Time In: 14:24 ☐ AM ☒ PM | Military: ☐ 2nd Day ☐ 3rd Day | Return Receipt Fee:

Weight: lbs. 12 ozs. | Int'l Alpha Country Code | COD Fee | Insurance Fee

No Delivery: ☐ Weekend ☐ Holiday | Acceptance Clerk Initials | Total Postage & Fees: $ 16.00

MAY 10 2001

SEE REVERSE SIDE FOR SERVICE GUARANTEE AND LIMITS ON INSURANCE COVERAGE

☐ WAIVER OF SIGNATURE (Domestic Only): Additional merchandise insurance is void if waiver of signature is requested. I wish delivery to be made without obtaining signature of addressee or addressee's agent (if delivery employee judges that article can be left in secure location) and I authorize that delivery employee's signature constitutes valid proof of delivery.

NO DELIVERY ☐ Weekend, ☐ Holiday — Customer Signature

CUSTOMER USE ONLY

METHOD OF PAYMENT:
Express Mail Corporate Acct. No: [illegible]
Federal Agency Acct. No. or Postal Service Acct. No.:

FROM: (PLEASE PRINT) PHONE (201) 487-5800

[illegible]

1300-1-038 (D. Jackson/Ts)

TO: (PLEASE PRINT) PHONE ( )

BOX PCT PATENT APPLICATION
ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.com

Customer Copy

Serial No. PCT/GB99/03747 File No. 1300-1-008 By DAJ/ls

Title ANTIBODY-SERUM PROTEIN HYBRIDS

In the Matter of the Application of Bryan John Smith

The following was received in the U.S. Patent & Trademark Office on the date stamped hereon: VIA EXPRESS MAIL #EL 758521582 US

09/831534

[X] Transmittal Sheet/Cover Ltr. in dup	[ ] Extension of Time
[X] Application For Patent	[ ] Issue Fee Transmittal
[X] Declaration [ ] Affidavit unexecuted	[ ] Maintenance Fee
[X] Drawings [X] Sheet(s) (9)	[ ] Appln. TM Registration
[ ] S.E. Verified Statements	[ ] 8 & 15 Declaration
[ ] Assignment	[ ] Renewal Application
[X] Check for $ 860.00	[ ] Notice of Appeal
[ ] Letter [ ] Missing Parts	[ ] Brief [ ] Petition
[ ] Priority Document	[ ] Power of Attorney
[X] Amendment [ ] Response PRELIMINARY	[X] copies of Intern'l Search Report; Exam Report; Written Opinion

JC17 Rec'd PCT/PTO 10 MAY 2001

DOCKETED CPI

OFFICIAL

Attorney Docket No.: 1300-1-308 10/3/02

-mo

#7

gms

VERSION WITH MARKINGS TO SHOW CHANGES MADE

3. (Amended) A hybrid protein according to Claim 1 [or Claim 2] wherein each serum carrier protein is thyroxine-binding protein, transthyretin, α1-acid glycoprotein, transferrin, fibrinogen or albumin or a fragment thereof.

4. (Amended) A hybrid protein according to Claim 1 [to Claim 3] wherein each antibody fragment is a monovalent Fab fragment optionally containing one or more additional amino acids attached to the C-terminus of the CH1 domain.

6. (Amended) A hybrid protein according to Claim 1 [any one of the preceding claims] comprising one antigen-binding antibody fragment covalently linked to an albumin molecule or a fragment thereof.

10. (Amended) A hybrid protein according to Claim 8 [or Claim 9] wherein the bridging molecule is from around 10A to around 20A in length.

12. (Amended) A hybrid protein according to Claim 1 [any one of the preceding claims] covalently linked to one or more effector or reporter groups.

13. (Amended) A pharmaceutical composition comprising a hybrid protein according to Claim 1 [any one of the preceding claims] together with one or more pharmaceutically acceptable excipients, diluents or carriers.